Related references
Note: Only part of the references are listed.Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
J. Simon R. Gibbs
HEART (2008)
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
C. P. Denton et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Quality of life in pulmonary arterial hypertension: Improvement and maintenance with bosentan
Anne M. Keogh et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
C. P. Denton et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
M. H. Williams et al.
HEART (2006)
Pulmonary arterial hypertension in France - Results from a national registry
M Humbert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
S Provencher et al.
EUROPEAN HEART JOURNAL (2006)
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing
John H. Wlodarczyk et al.
PHARMACOECONOMICS (2006)
Survival with first-line bosentan in patients with primary pulmonary hypertension
VV McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
The endothelin system in pulmonary arterial hypertension
N Galié et al.
CARDIOVASCULAR RESEARCH (2004)
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
O Sitbon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Health-related quality of life in patients with pulmonary arterial hypertension
S Shafazand et al.
CHEST (2004)
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension
N Galiè et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
RJ Barst et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
SM Kawut et al.
CHEST (2003)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
Share Paper
